

References

I-87

1. Richard PJ, Egan DN, Hendrie PC, Parvathaneni U. Plasmablastic lymphoma of the maxillary sinus: case report of a novel treatment approach of concurrent bortezomib and intensity-modulated radiotherapy. *Open J Hematol*. 2015;1-2.
2. Marschner N, Arnold D, Engel E, et al. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study. *Clin Epidemiol*. 2015; 295-303.
3. MICROMEDEX®SOLUTIONS Compendia. 2019. Oxaliplatin.
4. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. Oxaliplatin.
5. NCCN Drugs & Biologics Compendium™. Oxaliplatin. 2019. National Comprehensive Cancer Network (NCCN).
6. Liang R, Lin Y, Li Q, et al. Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: A phase-I clinical trial. *Mol-Clin Oncol*. 2017;6: 622-626.
7. Mukherjee S, Hurt CN, Gwynee S, et al. NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. *Eu J Cancer*. 2017; 38-46.
8. Eloxatin® (oxaliplatin) injection for intravenous use. [package insert]. Sanofi-Aventis LLC. Bridgewater, NJ. 2002. Revised 10/2015.